Insulin receptor substrate-2 mediated insulin-like growth factor-I receptor overexpression in pancreatic adenocarcinoma through protein kinase Cδ

Cancer Research

Volumn 69, Issue 4, 2009, Pages 1350-1357

  Kwon, Junhye ^a   Stephan, Susann ^b   Mukhopadhyay, Ananya ^a   Muders, Michael H ^a   Dutta, Shamit K ^a   Lau, Julie S ^a   Mukhopadhyay, Debabrata ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NEUTRALIZING ANTIBODY; PROTEIN KINASE C DELTA; RAPAMYCIN; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ADENOCARCINOMA; CELL DIVISION; CELL LINE, TUMOR; DNA PRIMERS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; PROTEIN BIOSYNTHESIS; PROTEIN KINASE C-DELTA; PROTEIN KINASES; RECEPTOR, IGF TYPE 1; RNA, NEOPLASM; RNA, SMALL INTERFERING;

EID: 60549112878     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1328     Document Type: Article

References (53)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Bauer TW, Somcio RJ, Fan F, et al. Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther 2006;5:1676-82.
3. Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 1995;55:2007-11.
4. Hakam A, Fang Q, Karl R, Coppola D. Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Dig Dis Sci 2003;48:1972-8.
5. Karna E, Surazynski A, Orlowski K, et al. Serum and tissue level of insulin-like growth factor-I (IGF-I) and IGF-I binding proteins as an index of pancreatitis and pancreatic cancer. Int J Exp Pathol 2002;83:239-45.
6. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1997;1332:F105-26.
7. Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene 2000;19:5574-81.
8. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000;183:1-9.
9. Nair PN, De Armond DT, Adamo ML, Strodel WE, Freeman JW. Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2. Oncogene 2001;20:8203-14.
10. Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 2001;61:589-93.
11. Flossmann-Kast BB, Jehle PM, Hoeflich A, Adler G, Lutz MP. Src stimulates insulin-like growth factor I (IGF-I)-dependent cell proliferation by increasing IGF-I receptor number in human pancreatic carcinoma cells. Cancer Res 1998;58:3551-4.
12. Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007;6:821-33.
13. Ebina Y, Ellis L, Jarnagin K, et al. The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. Cell 1985;40:747-58.
14. Ullrich A, Bell JR, Chen EY, et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 1985;313:756-61.
15. White MF, Shoelson SE, Keutmann H, Kahn CR. A cascade of tyrosine autophosphorylation in the β-subunit activates the phosphotransferase of the insulin receptor. J Biol Chem 1988;263:2969-80.
16. Gibson SL, Ma Z, Shaw LM. Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis. Cell Cycle 2007;6:631-7.
17. Myers MG, Jr., White MF. The new elements of insulin signaling. Insulin receptor substrate-1 and proteins with SH2 domains. Diabetes 1993;42:643-50.
18. Uchida T, Myers MG, Jr., White MF. IRS-4mediates protein kinase B signaling during insulin stimulation without promoting antiapoptosis. Mol Cell Biol 2000;20:126-38.
19. Kornmann M, Maruyama H, Bergmann U, et al. Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer. Cancer Res 1998;58:4250-4.
20. Cheadle JP, Reeve MP, Sampson JR, Kwiatkowski DJ. Molecular genetic advances in tuberous sclerosis. Hum Genet 2000;107:97-114.
21. Potter CJ, Huang H, Xu T. Drosophila Tscl functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 2001;105:357-68.
22. Wienecke R, Maize JC, Jr., Shoarinejad F, et al. Co-localization of the TSC2 product tuberin with its target Rap1 in the Golgi apparatus. Oncogene 1996;13:913-23.
23. Avruch J, Hara K, Lin Y, et al. Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene 2006;25:6361-72.
24. Kataoka K, Fujimoto K, Ito D, et al. Expression and prognostic value of tuberous sclerosis complex 2 gene product tuberin in human pancreatic cancer. Surgery 2005;138:450-5.
25. Astrinidis A, Henske EP. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 2005;24:7475-81.
26. Tee AR, Blenis J. mTOR, translational control and human disease. Semin Cell Dev Biol 2005;16:29-37.
27. Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 1992;257:973-7.
28. Beretta L, Gingras AC, Svitkin YV, Hall MN, Sonen-berg N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation oftranslation. EMBO J 1996;15:658-64.
29. Rousseau D, Gingras AC, Pause A, Sonenberg N. The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 1996;13:2415-20.
30. Kumar V, Pandey P, Sabatini D, et al. Functional interaction between RAFTl/FRAP/mTOR and protein kinase C6 in the regulation of cap-dependent initiation of translation. EMBO J 2000;19:1087-97.
31. Dekker LV Parker PJ. Protein kinase C-a question of specificity. Trends Biochem Sci 1994;19:73-7.
32. Easton JB, Kurmasheva RT, Houghton PJ. IRS-1: auditing the effectiveness of mTOR inhibitors. Cancer Cell 2006;9:153-5.
33. Datta K, Nambudripad R, Pal S, Zhou M, Cohen HT, Mukhopadhyay D. Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J Biol Chem 2000;275:20700-6.
34. Li W, Jiang YX, Zhang J, et al. Protein kinase C-δ is an important signaling molecule in insulin-like growth factor I receptor-mediated cell transformation. Mol Cell Biol 1998;18:5888-98.
35. Yenush L, Zanella C, Uchida T, Bernal D, White MF. The pleckstrin homology and phosphotyrosine binding domains of insulin receptor substrate 1 mediate inhibition of apoptosis by insulin. Mol Cell Biol 1998;18:6784-94.
36. Khosravi-Far R, White MA, Westwick JK, et al. Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol Cell Biol 1996;16:3923-33.
37. Chou MM, Hou W, Johnson J, et al. Regulation of protein kinase Cζ by PI 3-kinase and PDK-1. Curr Biol 1998;8:1069-77.
38. Ohmura E, Okada M, Onoda N, et al. Insulin-like growth factor I and transforming growth factor a as autocrine growth factors in human pancreatic cancer cell growth. Cancer Res 1990;50:103-7.
39. Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999;344:427-31.
40. Watanabe M, Nobuta A, Tanaka J, Asaka M. An effect of K-ras gene mutation on epidermal growth factor receptor signal transduction in PANC-1 pancreatic carcinoma cells. Int J Cancer 1996;67:264-8.
41. Barton CM, Staddon SL, Hughes CM, et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991;64:1076-82.
42. Asano T, Yao Y, ZhuJ, Li D, Abbruzzese JL, ReddySA. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells. Oncogene 2004;23:8571-80.
43. Gao X, Zhang Y, Arrazola P, et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 2002;4:699-704.
44. Goncharova EA, Goncharov DA, Eszterhas A, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphan-gioleiomyomatosis (LAM). J Biol Chem 2002;277:30958-67.
45. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 2002;99:13571-6.
46. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-83.
47. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48.
48. Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 2005;19:1773-8.
49. Kaleko M, Rutter WJ, Miller AD. Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 1990;10:464-73.
50. Sell C, Baserga R, Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 1995;55:303-6.
51. Zeng H, Datta K, Neid M, Li J, Parangi S, Mukhopadhyay D. Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res Commun 2003;302:46-55.
52. Tamburini J, Chapuis N, Bardet V, et al. Mammalian target of rapamycin (mTOR) inhibition activates phos-phatidylinositol 3-kinase/Akt by up-regulating insulinlike growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008;111:379-82.
53. Giovannone B, Scaldaferri ML, Federici M, et al. Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential. Diabetes Metab Res Rev 2000;16:434-41.